Cellectar Reports Q3 26 Results, Updates Iopofosine I 131 Roadmap
Cellectar Biosciences announced financial results and corporate updates, highlighted by new efficacy data supporting accelerated approval for iopofosine I 131 and a plan to file an NDA in the first half of 2027.
AI-generated summary for informational purposes only. Always verify against the original filing. Not investment advice. BriefTape is not a registered investment adviser.
Get real-time financial news in your trading bot or app
START FREE — 10,000 calls/day, no key needed